Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

about

Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q53614521

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@en

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@nl

type

Item

label

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@en

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@nl

prefLabel

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@en

Bicalutamide 150 mg as seconda ...... ion-resistant prostate cancer.

@nl

P1476

Bicalutamide 150 mg as seconda ...... tion-resistant prostate cancer

@en

P2093

Hai-bo Shen

http://www.w3.org/2001/XMLSchema#string

Lin Zhang

http://www.w3.org/2001/XMLSchema#string

Qi-feng Cao

http://www.w3.org/2001/XMLSchema#string

Su-bo Qian

http://www.w3.org/2001/XMLSchema#string

Yi-fan Chen

http://www.w3.org/2001/XMLSchema#string

P2860

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus

Cancer statistics, 2005

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Transcriptional repression by nuclear hormone receptors.

Secondary hormonal therapy for advanced prostate cancer.

Advances in androgen receptor targeted therapy for prostate cancer

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

P304

479-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11255-015-0919-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jun Qi

P577

2015-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25665794

http://www.w3.org/2001/XMLSchema#string